83-5969-95　Secukinumab Biosimilar, Human IL17A 5mg　592184

特徴

• Research grade secukinumab biosimilar uses the same protein sequences as the therapeutic antibody secukinumab.
• Secukinumab, the humanized anti-IL17A monoclonal antibody, inhibits interleukin 17A, which is a member of the cytokine family, and produced mainly by inflammatory T helper 17 cells.
• IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin.
• Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Secukinumab.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.